US will not give green light to AstraZeneca, says medical board Covid-19 USA | NRI

HOUSTON: Health officials and the medical board say they do not have full confidence in the vaccine report released yesterday by AstraZeneca. AstraZeneca released the vaccine trial results on Monday following approval by the medical board. However, it is now clear that they do not agree. The Medical Board argues that this hasty trial does not undermine the trust of the authorities and therefore requires more data. However, AstraZeneca claimed that their vaccine was 79% effective in this trial. Earlier, several European countries suspended the vaccine following allegations that it could cause serious health problems. This was followed by the AstraZeneca trial in the US, which claimed great success. Opposition to this has now come from the US itself. The Swedish company has suffered a setback as it seeks FDA approval in the coming days. Only three vaccines are still approved in the US.


Federal health officials on Tuesday expressed suspicion that the AstraZeneca Kovid 19 vaccine may have relied on ‘outdated information’. They raised doubts in a statement announced Monday that ‘may have given an incomplete view of the effectiveness data’. They are preparing for the US trial following the setback in Europe for AstraZeneca, which has made great strides in the global vaccination drive. The goal was to get FDA approval by any means, but now the chances are slim. The United States has already turned its back on the vaccine, which was developed by Oxford University. Moreover, the current situation of three vaccine distributions suggests that a fourth may not be approved immediately. In addition, the FADA will examine all aspects of a defamatory vaccine before approving it. In a very unusual statement released after midnight, the Data and Safety Monitoring Board, an independent panel of medical experts under the National Institutes of Epidemic Disease and the National Institute of Health, expressed doubts about AstraZeneca’s trial data.


The Institute requested Astraseneka to review the effectiveness data and to work with the Monitoring Board to ensure that the most accurate and up-to-date effectiveness data is made public as soon as possible. AstraZeneca may not immediately respond to the statement Tuesday morning. Announcing the results of the U.S. trial, the company said in a press release on Monday that the vaccine developed at Oxford University was 79 percent effective against Covid 19, which was higher than what had been seen in previous experiments, and completely blocked the latest germs. These results were seen as promoting global confidence in the vaccine. This month, more than a dozen countries in Europe suspended the use of the shot due to concerns about rare side effects.


After a review, Europe’s best drug regulator last week said the shot was ‘safe and effective.’ That was it. Companies sponsoring drug or vaccine trials would usually wait for the monitoring board to conduct analyzes and conduct a large-scale study before announcing trial results. In recent days, the Monitoring Board’s analysis of AstraSeneca’s trial has been delayed several times because the board has requested updated reports from those who handle trial data on behalf of the company. But it must be assumed that it was not received. This is now public. The Monitoring Board finally announced the study results to AstraZeneca at a meeting over the weekend. This led to the company’s announcement on Monday morning.

He is a clinical trials specialist at Scripps Research in San Diego. Eric Topol said such conflicts between a monitoring board and a study sponsor are publicly ‘very irregular’ and are usually close. In an interview after the Institute’s statement was released, he commented, ‘I have never seen anything like this.

Millions of people around the world have received the AstraZeneca shot, and almost everyone has received it without serious side effects, including more than 17 million people in the UK and the European Union. Several European political leaders have received injections in recent days to boost public confidence. Leaders in South Korea, Taiwan and Thailand also received the AstraZeneca vaccine last week.